Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Donatello SalvatoreVincenzo CarnovalePaola IacotucciCesare BraggionCarlo CastellaniGiuseppe CiminoCarmela ColangeloMichela FrancalanciGiuseppina LeonettiVincenzina LucidiAntonio MancaPamela VitulloNicola FerraraPublished in: Pediatric pulmonology (2019)
Ivacaftor was safe and effective in patients with CF with severe lung disease and non-G551D gating mutations.